|Bid||17.00 x 800|
|Ask||22.05 x 800|
|Day's Range||18.65 - 19.25|
|52 Week Range||10.85 - 31.99|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.00|
Biodesix releases new data at AACR annual meeting on the use of proteomic profiling to help guide physician treatment strategies for NSCLC patients.
Biodesix receives two important U.S. patents for diagnostic methods, which seek to improve care for cancer patients.
Biodesix announces the closing of a $30 million term loan.